Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: Comparison between FISH and RT-PCR

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Fernandez Serra A ^a   Rubio, L ^a   Calatrava, A ^a   Rubio Briones, J ^a   Salgado, R ^b   Gil Benso, R ^c   Espinet, B ^b   Garcia Casado Z ^a   Lopez Guerrero J A ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL TRANSFORMATION; CONTROLLED STUDY; ERYTHROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GENE TRANSLOCATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PERINEURAL INVASION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR;

AVES;

DEMOGRAPHY; DISEASE-FREE SURVIVAL; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; ONCOGENE PROTEINS, FUSION; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84879399894     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/465179     Document Type: Article

References (43)

1. Hayes J. H., Ollendorf D. A., Pearson S. D., Barry M. J., Kantoff P. W., Stewart S. T., Bhatnagar V., Sweeney C. J., Stahl J. E., McMahon P. M., Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. Journal of the American Medical Association 2010 304 21 2373 2380 2-s2.0-78649743564 10.1001/jama.2010.1720
2. Thomson A. H., Kulkarni S., Bahl A., Primary cryotherapy with salvage external beam radiotherapy for locally recurrent prostate cancer. Clinical Oncology 2008 20 5 385 2-s2.0-43049154800 10.1016/j.clon.2008.03.009
3. Rabbani F., Stroumbakis N., Kava B. R., Cookson M. S., Fair W. R., Incidence and clinical significance of false-negative sextant prostate biopsies. The Journal of Urology 1998 159 4 1247 1250 2-s2.0-0031897085 10.1016/S0022-5347(01)63574-2 (Pubitemid 28172807)
4. Tomlins S. A., Rhodes D. R., Perner S., Dhanasekaran S. M., Mehra R., Sun X. W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J. E., Shah R. B., Pienta K. J., Rubin M. A., Chinnaiyan A. M., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 310 5748 644 648 2-s2.0-27344451557 10.1126/science.1117679 (Pubitemid 41528150)
5. Tomlins S. A., Mehra R., Rhodes D. R., Smith L. R., Roulston D., Helgeson B. E., Cao X., Wei J. T., Rubin M. A., Shah R. B., Chinnaiyan A. M., TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Research 2006 66 7 3396 3400 2-s2.0-33645750799 10.1158/0008-5472.CAN-06- 0168
6. Narod S. A., Seth A., Nam R., Fusion in the ETS gene family and prostate cancer. British Journal of Cancer 2008 99 6 847 851 2-s2.0-51449107401 10.1038/sj.bjc.6604558
7. Tomlins S. A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B. E., Cao Q., Prensner J. R., Rubin M. A., Shah R. B., Mehra R., Chinnaiyan A. M., Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008 10 2 177 188 2-s2.0-39049150843 10.1593/neo.07822 (Pubitemid 351240884)
8. Tomlins S. A., Bjartell A., Chinnaiyan A. M., Jenster G., Nam R. K., Rubin M. A., Schalken J. A., ETS gene fusions in prostate cancer: from discovery to daily clinical practice. European Urology 2009 56 2 275 286 2-s2.0-67649425225 10.1016/j.eururo.2009.04.036
9. Fernández-Serra A., Rubio-Briones J., García-Casado Z., Solsona E., López-Guerrero J. A., Prostate cancer: the revolution of the fusion genes. Actas Urologicas Espanolas 2011 35 7 420 428 2-s2.0-79958096047 10.1016/j.acuro.2010.11.019
10. Sun Q. P., Li L. Y., Chen Z., Pang J., Yang W. J., Zhou X. F., Qiu J. G., Su Z. L., He D., Gao X., Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. Journal of Molecular Diagnostics 2010 12 5 718 724 2-s2.0-77956800934 10.2353/jmoldx.2010.100002
11. Yoshimoto M., Cutz J. C., Nuin P. A. S., Joshua A. M., Bayani J., Evans A. J., Zielenska M., Squire J. A., Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics 2006 169 2 128 137 2-s2.0-33747842237 10.1016/j.cancergencyto. 2006.04.003 (Pubitemid 44287105)
12. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs G., Flohr P., Berney D., Foster C. S., Fletcher A., Gerald W. L., Moller H., Reuter V., De Bono J. S., Scardino P., Cuzick J., Cooper C. S., Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008 27 3 253 263 2-s2.0-38049123346 10.1038/sj.onc.1210640
13. Attard G., Clark J., Ambroisine L., Mills I. G., Fisher G., Flohr P., Reid A., Edwards S., Kovacs G., Berney D., Foster C., Massie C. E., Fletcher A., De Bono J. S., Scardino P., Cuzick J., Cooper C. S., Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. British Journal of Cancer 2008 99 2 314 320 2-s2.0-48249150750 10.1038/sj.bjc.6604472
14. Perner S., Demichelis F., Beroukhim R., Schmidt F. H., Mosquera J. M., Setlur S., Tchinda J., Tomlins S. A., Hofer M. D., Pienta K. G., Kuefer R., Vessella R., Sun X. W., Meyerson M., Lee C., Sellers W. R., Chinnaiyan A. M., Rubin M. A., TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research 2006 66 17 8337 8341 2-s2.0-33749029695 10.1158/0008-5472.CAN-06-1482 (Pubitemid 44449140)
15. Lu B., Maqsodi B., Yang W., McMaster G. K., Perner S., Regan M., Bubley G. J., Balk S. P., Rubin M., Sanda M. G., Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology 2009 74 5 1156 1161 2-s2.0-70350443351 10.1016/j.urology.2009.01.087
16. Yoshimoto M., Joshua A. M., Chilton-MacNeill S., Bayani J., Selvarajah S., Evans A. J., Zielenska M., Squire J. A., Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006 8 6 465 469 2-s2.0-33745808783 10.1593/neo.06283 (Pubitemid 44035330)
17. Demichelis F., Fall K., Perner S., Andrén O., Schmidt F., Setlur S. R., Hoshida Y., Mosquera J. M., Pawitan Y., Lee C., Adami H. O., Mucci L. A., Kantoff P. W., Andersson S. O., Chinnaiyan A. M., Johansson J. E., Rubin M. A., TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007 26 31 4596 4599 2-s2.0-34248510706 10.1038/sj.onc.1210237 (Pubitemid 47037039)
18. Rubio-Briones J., Fernández-Serra A., Calatrava A., García-Casado Z., Rubio L., Bonillo M. A., Iborra I., Solsona E., López-Guerrero J. A., Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. The Journal of Urology 2010 183 5 2054 2061 2-s2.0-77950471832 10.1016/j.juro.2009.12.096
19. Djavan B., Remzi M., Schulman C. C., Marberger M., Zlotta A. R., Repeat prostate biopsy: who, how and when? A review. European Urology 2002 42 2 93 103 2-s2.0-0036668361 10.1016/S0302-2838(02)00256-7
20. Mosquera J. M., Perner S., Genega E. M., Sanda M., Hofer M. D., Mertz K. D., Paris P. L., Simko J., Bismar T. A., Ayala G., Shah R. B., Loda M., Rubin M. A., Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clinical Cancer Research 2008 14 11 3380 3385 2-s2.0-50349093250 10.1158/1078-0432.CCR-07-5194
21. Tu J. J., Rohan S., Kao J., Kitabayashi N., Mathew S., Chen Y. T., Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Modern Pathology 2007 20 9 921 928 2-s2.0-34547936357 10.1038/modpathol.3800903 (Pubitemid 47267823)
22. Yoshimoto M., Joshua A. M., Cunha I. W., Coudry R. A., Fonseca F. P., Ludkovski O., Zielenska M., Soares F. A., Squire J. A., Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology 2008 21 12 1451 1460 2-s2.0-56649091295 10.1038/modpathol.2008.96
23. Pflueger D., Rickman D. S., Sboner A., Perner S., LaFargue C. J., Svensson M. A., Moss B. J., Kitabayashi N., Pan Y., De La Taille A., Kuefer R., Tewari A. K., Demichelis F., Chee M. S., Gerstein M. B., Rubin M. A., N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009 11 8 804 811 2-s2.0-67650489112 10.1593/neo.09572
24. Han B., Mehra R., Dhanasekaran S. M., Yu J., Menon A., Lonigro R. J., Wang X., Gong Y., Wang L., Shankar S., Laxman B., Shah R. B., Varambally S., Palanisamy N., Tomlins S. A., Kumar-Sinha C., Chinnaiyan A. M., A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Research 2008 68 18 7629 7637 2-s2.0-54749111457 10.1158/0008-5472.CAN-08-2014
25. Soller M. J., Isaksson M., Elfving P., Soller W., Lundgren R., Panagopoulos I., Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes and Cancer 2006 45 7 717 719 2-s2.0-33646580105 10.1002/gcc.20329 (Pubitemid 43727158)
26. Tomlins S. A., Mehra R., Rhodes D. R., Cao X., Wang L., Dhanasekaran S. M., Kalyana-Sundaram S., Wei J. T., Rubin M. A., Pienta K. J., Shah R. B., Chinnaiyan A. M., Integrative molecular concept modeling of prostate cancer progression. Nature Genetics 2007 39 1 41 51 2-s2.0-33845884027 10.1038/ng1935 (Pubitemid 46026500)
27. Machado I., Noguera R., Pellin A., Lopez-Guerrero J. A., Piqueras M., Navarro S., Llombart-Bosch A., Molecular diagnosis of ewing sarcoma family of tumors: a comparative analysis of 560 cases with fish and rt-pcr. Diagnostic Molecular Pathology 2009 18 4 189 199 2-s2.0-73349131509 10.1097/PDM. 0b013e3181a06f66
28. Salgado R., Llombart B., Pujol R. M., Fernández-Serra A., Sanmartín O., Toll A., Rubio L., Segura S., Barranco C., Serra-Guillén C., Yébenes M., Salido M., Traves V., Monteagudo C., Sáez E., Hernández T., de Álava E., Llombart-Bosch A., Solé F., Guillén C., Espinet B., López-Guerrero J. A., Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes and Cancer 2011 50 7 510 517 2-s2.0-79955664776 10.1002/gcc.20874
29. Hermans K. G., Boormans J. L., Gasi D., Van Leenders G. J. H. L., Jenster G., Verhagen P. C. M. S., Trapman J., Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clinical Cancer Research 2009 15 20 6398 6403 2-s2.0-70350231922 10.1158/1078-0432.CCR-09-1176
30. Wang J., Cai Y., Ren C., Ittmann M., Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Research 2006 66 17 8347 8351 2-s2.0-33749034498 10.1158/0008-5472.CAN-06-1966 (Pubitemid 44449142)
31. Bridge R. S., Rajaram V., Dehner L. P., Pfeifer J. D., Perry A., Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Modern Pathology 2006 19 1 1 8 2-s2.0-32844474047 10.1038/modpathol.3800486 (Pubitemid 43250973)
32. Lewis T. B., Coffin C. M., Bernard P. S., Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues. Modern Pathology 2007 20 3 397 404 2-s2.0-33847399257 10.1038/modpathol.3800755 (Pubitemid 46348340)
33. Wallander M. L., Geiersbach K. B., Tripp S. R., Layfield L. J., Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Archives of Pathology & Laboratory Medicine 2012 136 7 796 803
34. Dvorak L., Dolan M., Fink J., Varghese L., Henriksen J., Gulbahce H. E., Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test. Applied Immunohistochemistry & Molecular Morphology 2013 21 3 196 199
35. Baehner F. L., Achacoso N., Maddala T., Shak S., Quesenberry C. P., Goldstein L. C., Gown A. M., Habel L. A., Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. Journal of Clinical Oncology 2010 28 28 4300 4306 2-s2.0-78049427278 10.1200/JCO.2009.24.8211
36. Folpe A. L., Goldblum J. R., Rubin B. P., Shehata B. M., Liu W., Dei Tos A. P., Weiss S. W., Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. American Journal of Surgical Pathology 2005 29 8 1025 1033 2-s2.0-22944442294 (Pubitemid 41045546)
37. Kumar S., Pack S., Kumar D., Walker R., Quezado M., Zhuang Z., Meltzer P., Tsokos M., Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue. Human Pathology 1999 30 3 324 330 2-s2.0-0032979365 (Pubitemid 29125153)
38. Fritsch M. K., Bridge J. A., Schuster A. E., Perlman E. J., Argani P., Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatric and Developmental Pathology 2003 6 1 43 53 2-s2.0-0347926517 10.1007/s10024-002-0013-1 (Pubitemid 36323626)
39. Saramäki O. R., Harjula A. E., Martikainen P. M., Vessella R. L., Tammela T. L. J., Visakorpi T., TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clinical Cancer Research 2008 14 11 3395 3400 2-s2.0-50349102353 10.1158/1078-0432.CCR-07-2051
40. Petrovics G., Liu A., Shaheduzzaman S., Furasato B., Sun C., Chen Y., Nau M., Ravindranath L., Chen Y., Dobi A., Srikantan V., Sesterhenn I. A., McLeod D. G., Vahey M., Moul J. W., Srivastava S., Frequent overexpression of ETS -related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005 24 23 3847 3852 2-s2.0-20444493600 10.1038/sj.onc.1208518 (Pubitemid 40826884)
41. Rajput A. B., Miller M. A., de Luca A., Boyd N., Leung S., Hurtado-Coll A., Fazli L., Jones E. C., Palmer J. B., Gleave M. E., Cox M. E., Huntsman D. G., Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Journal of Clinical Pathology 2007 60 11 1238 1243 2-s2.0-33947590808 10.1136/jcp.2006.043810 (Pubitemid 350084545)
42. Gopalan A., Leversha M. A., Satagopan J. M., Zhou Q., Al-Ahmadie H. A., Fine S. W., Eastham J. A., Scardino P. T., Scher H. I., Tickoo S. K., Reuter V. E., Gerald W. L., TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Research 2009 69 4 1400 1406 10.1158/0008-5472.CAN-08-2467
43. Tomlins S. A., Aubin S. M., Siddiqui J., Lonigro R. J., Sefton-Miller L., Miick S., Williamsen S., Hodge P., Meinke J., Blase A., Penabella Y., Day J. R., Varambally R., Han B., Wood D., Wang L., Sanda M. G., Rubin M. A., Rhodes D. R., Hollenbeck B., Sakamoto K., Silberstein J. L., Fradet Y., Amberson J. B., Meyers S., Palanisamy N., Rittenhouse H., Wei J. T., Groskopf J., Chinnaiyan A. M., Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Science Translational Medicine 2011 3 94 94ra72 10.1126/scitranslmed.3001970